Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer

Histopathology

Volumn 55, Issue 1, 2009, Pages 28-36

  Cooper, Wendy A ^a   Kohonen Corish, Maija R J ^b   McCaughan, Brian ^a   Kennedy, Catherine ^c   Sutherland, Robert L ^b   Lee, Cheok Soon ^a,c,d  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d University of Sydney   (Australia)

Author keywords

Cyclin A; Cyclin B1; Immunohistochemistry; Lung neoplasm; Non small cell lung cancer; Prognosis

Indexed keywords

CYCLIN A; CYCLIN B1;

ADULT; AGED; ARTICLE; BRONCHUS MUCOSA; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SEX DIFFERENCE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL CYCLE; CYCLIN A; CYCLIN B; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRECANCEROUS CONDITIONS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 68049120610     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03331.x     Document Type: Article

References (48)

1. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004 432 316.
2. Cordon-Cardo C. Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am. J. Pathol. 1995 147 545 560.
3. Nesbitt JC, Putnam JB, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann. Thorac. Surg. 1995 60 466.
4. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol. 2006 59 790 800.
5. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC eds. World Health Organisation classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon : IARC Press, 2004.
6. Greene FL, Page DL, Fleming ID et al. eds. AJCC cancer staging manual, 6th edn. Chicago : Springer-Verlag, 2002.
7. Cooper WA, Kohonen-Corish MRJ, Chan C et al. Prognostic significance of DNA repair proteins MLH1, MSH2 and MGMT expression in non-small cell lung cancer and precursor lesions. Histopathology 2008 52 613 622.
8. Chen H-M, Yen-Ping Kuo M, Lin K-H, Lin C-Y, Chiang C-P. Expression of cyclin A is related to progression of oral squamous cell carcinoma in Taiwan. Oral Oncol. 2003 39 476.
9. Kühling H, Alm P, Olsson H et al. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer. J. Pathol. 2003 199 424 431.
10. Murakami H, Furihata M, Ohtsuki Y, Ogoshi S. Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma. Virchows Arch. 1999 434 153 158.
11. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann. Oncol. 2004 15 252 256.
12. Soria JC, Jang SJ, Khuri FR et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000 60 4000 4004.
13. Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol. Immunol. 2002 38 981.
14. D'Andrea MR, Limiti MR, Bari M et al. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis. Breast Cancer Res. Treat. 2007 101 279 284.
15. Kallakury BS, Sheehan CE, Rhee SJ et al. The prognostic significance of proliferation-associated nucleolar protein p120 expression in prostate adenocarcinoma. Cancer 1999 85 1569 1576.
16. Hassan KA, El-Naggar AK, Soria JC, Liu D, Hong WK, Mao L. Clinical significance of cyclin B1 protein expression in squamous cell carcinoma of the tongue. Clin. Cancer Res. 2001 7 2458 2462.
17. Kushner J, Bradley G, Young B, Jordan RCK. Aberrant expression of cyclin A and cyclin B1 proteins in oral carcinoma. J. Oral Pathol. Med. 1999 28 77 81.
18. Dong Y, Sui L, Watanabe Y, Sugimoto K, Tokuda M. Clinical relevance of cyclin B1 overexpression in laryngeal squamous cell carcinoma. Cancer Lett. 2002 177 13.
19. Galizia G, Ferraraccio F, Lieto E et al. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J. Surg. Oncol. 2006 93 241 252.
20. Grabsch H, Lickvers K, Hansen O et al. Prognostic value of cyclin B1 protein expression in colorectal cancer. Am. J. Clin. Pathol. 2004 122 511 516.
21. Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T, Inutsuka S. The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery 2002 131 S114 S120.
22. Ikuerowo SO, Kuczyk MA, Mengel M et al. Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int. J. Cancer 2006 119 867 874.
23. Taylor WR, DePrimo SE, Agarwal A et al. Mechanisms of G2 arrest in response to overexpression of p53. Mol. Biol. Cell 1999 10 3607 3622.
24. Yin X-Y, Grove L, Datta NS, Katula K, Long MW, Prochownik EV. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res. 2001 61 6487 6493.
25. Nozoe T, Korenaga D, Kabashima A, Ohga T, Saeki H, Sugimachi K. Significance of cyclin B1 expression as an independent prognostic indicator of patients with squamous cell carcinoma of the esophagus. Clin. Cancer Res. 2002 8 817 822. (Pubitemid 34742113)
26. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E. Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J. 1998 17 2728 2735.
27. De Souza CPC, Ellem KAO, Gabrielli BG. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp. Cell Res. 2000 257 11.
28. Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Müller W. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer 2002 94 2874 2881. (Pubitemid 34547686)
29. Scott IS, Morris LS, Bird K et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J. Pathol. 2003 201 187 197.
30. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 2005 11 1521 1526.
31. Rudolph P, Kühling H, Alm P et al. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer. Int. J. Cancer 2003 105 674 680.
32. Winters ZE, Hunt NC, Bradburn MJ et al. Subcellular localisation of cyclin B, Cdc2 and p21WAF1/CIP1 in breast cancer: association with prognosis. Eur. J. Cancer 2001 37 2405.
33. Yasuda M, Takesue F, Inutsuka S, Honda M, Nozoe T, Korenaga D. Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study. J. Cancer Res. Clin. Oncol. 2002 128 412 416.
34. Dobashi Y, Shoji M, Jiang S-X, Kobayashi M, Kawakubo Y, Kameya T. Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am. J. Pathol. 1998 153 963 972.
35. Muller-Tidow C, Metzger R, Kugler K et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res. 2001 61 647 653.
36. Furihata M, Ishikawa T, Inoue A et al. Determination of the prognostic significance of unscheduled cyclin A overexpression in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 1996 2 1781 1785.
37. Bahnassy A, Zekri A-R, El-Houssini S et al. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004 4 22.
38. Bukholm IRK, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int. J. Cancer 2001 93 283 287.
39. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinicopathological variables and patient survival. Prostate 1999 38 175 182. (Pubitemid 29054933)
40. Aaltomaa S, Lipponen P, Ala-Opas M, Eskelinen M, Syrjanen K, Kosma V-M. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival. Br. J. Cancer 1999 80 2001 2007. (Pubitemid 29391288)
41. Chao Y, Shih Y-L, Chiu J-H et al. Overexpression of cyclin A but not Skp2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 1998 58 985 990.
42. Volm M, Koomagi R, Mattern J, Stammler G. Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinoma. Br. J. Cancer 1997 75 1774 1778.
43. Patel RS, Hughes CW, Fredericks S et al. Cyclin A expression and its diagnostic value in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 2007 51 21 25. (Pubitemid 46976375)
44. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimäki A. Prognostic significance of cyclin A in gastric cancer. Int. J. Cancer 2006 119 1897 1901.
45. Rodriguez-Pinilla M, Rodriguez-Peralto JL, Hitt R et al. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer. Clin. Cancer Res. 2004 10 8486 8492.
46. Bondi J, Husdal A, Bukholm G, Nesland JM, Bakka A, Bukholm IRK. Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome. J. Clin. Pathol. 2005 58 509 514.
47. Volm M, Rittgen W, Drings P. Prognostic significance of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer 1998 77 663 669.
48. Dobashi Y, Jiang SX, Shoji M, Morinaga S, Kameya T. Diversity in expression and prognostic significance of G1/S cyclins in human primary lung carcinomas. J. Pathol. 2003 199 208 220.